TRACON Pharmaceuticals (NASDAQ:TCON) is set to release its earnings data after the market closes on Wednesday, November 7th. Analysts expect TRACON Pharmaceuticals to post earnings of ($0.27) per share for the quarter.
TRACON Pharmaceuticals (NASDAQ:TCON) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.02). On average, analysts expect TRACON Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of TCON traded up $0.11 during mid-day trading on Thursday, reaching $1.51. The company had a trading volume of 1 shares, compared to its average volume of 113,094. The firm has a market cap of $42.37 million, a PE ratio of -1.30 and a beta of 1.87. TRACON Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $3.60. The company has a quick ratio of 4.84, a current ratio of 4.84 and a debt-to-equity ratio of 0.17.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD.
Featured Story: What kind of dividend yield to CEF’s pay?
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.